<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00103506</url>
  </required_header>
  <id_info>
    <org_study_id>CR004117</org_study_id>
    <secondary_id>DOXILMMY3001</secondary_id>
    <secondary_id>2004-001842-34</secondary_id>
    <nct_id>NCT00103506</nct_id>
  </id_info>
  <brief_title>Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma</brief_title>
  <official_title>A Randomized Controlled Study of DOXIL/CAELYX (Doxorubicin HCL Liposome Injection) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate time to progression, overall survival, response rate
      and safety for the two open-label treatment groups; DOXIL/CAELYX in combination with VELCADE
      vs. VELCADE monotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized (study drug assigned by chance), parallel-group, open-label (all
      involved people know the identity of the intervention), multicenter study in 18 countries. A
      total of 646 patients with multiple myeloma whose disease has progressed after an initial
      response to at least 1 line of prior therapy or was refractory to initial treatment will be
      enrolled. The primary endpoint is time to progression (the interval between the date of
      randomization and the date of disease progression); secondary endpoints are overall survival
      (the interval between the date of randomization and the patient's death from any cause),
      response rate (the proportion of patients in the evaluable population who achieved a complete
      or partial response), and safety. Other study endpoints include patient reported outcomes and
      exploratory pharmacogenics (to identify genetic markers of response). Patients are assessed
      for efficacy and safety every 3 weeks until disease progression is documented or for up to 42
      weeks from the start of the first dose of study drug. Patients, who do not progress after the
      42-week period, are assessed every 6 weeks until disease progression is documented. Efficacy
      evaluations includes: serum protein electrophoresis, 24-hour urine collection for protein
      electrophoresis, skeletal survey (plain films), bone marrow biopsy and aspirate, clinical or
      radiologic assessment of plasmacytomas, and serum calcium. Responses and progressions are
      assessed objectively by a computer algorithm based on the EBMT criteria. Safety evaluations
      include adverse event reports, changes in clinical laboratory findings, and tests for cardiac
      function (multiple gated acquisition scan/echocardiogram and electrocardiogram). Group A:
      VELCADE monotherapy: VELCADE 1.3 milligram per meter square (mg/m^2) to be administered by
      i.v. bolus on Days 1, 4, 8, and 11 of each 21-day cycle. Group B: DOXIL/VELCADE combination:
      treated with VELCADE at the same dose and schedule as specified in Group A. DOXIL/CAELYX 30
      mg/m^2 by intravenous infusion given on Day 4 of every 21-day cycle following the
      administration of VELCADE.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>Up to 1 year and 4 months (From date of first participant randomization [20 December 2004] up to interim analysis cut-off date [28 April 2006])</time_frame>
    <description>Median time to progression of disease is assessed according to International Myeloma Working Group (IMWG) criteria or death from any cause. IMWG criteria: increase of &gt;=25% from lowest level in Serum M-component or (the absolute increase must be &gt;=0.5 gram per deciliter [g/dL]); Urine M component or (the absolute increase must be &gt;=200 milligram per 24 hour. Only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels. The absolute increase &gt;10 mg/dL. Bone marrow plasma cell percentage &gt;=10%. Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing. Development of hypercalcemia. Participants who died or dropped out due to any reason without progression will be censored with the day of death or drop-out, respectively and who are alive at the end of the study without any progression was censored with the last available date.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 9 years and 5 months (From date of first participant randomization [20 December 2004] to cut-off date for final survival analysis (16 May 2014)</time_frame>
    <description>The OS is defined as the time from the date of first dose of study drug to date of death from any cause. If the participant is alive or the vital status is unknown, the participant will be censored at the date the participant will be last known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 1 year and 11 months (From date of first participant randomization [20 December 2004] to cut-off date for safety update (28 November 2006)</time_frame>
    <description>A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">646</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>VELCADE (bortezomib) monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bortezomib (VELCADE) 1.3 milligram per meter square (mg/m^2) by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DOXIL/CAELYX in combination with VELCADE (bortezomib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bortezomib (VELCADE) 1.3 mg/m^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles. Doxorubicin hydrochloride (DOXIL/CAELYX) 30 mg/m2 by i.v. infusion will be given on Day 4 of every 21-day cycle after the administration of bortezomib (VELCADE) for up to 8 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib (VELCADE)</intervention_name>
    <description>1.3 mg/m^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles.</description>
    <arm_group_label>VELCADE (bortezomib) monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib (VELCADE)</intervention_name>
    <description>1.3 mg/m^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles..</description>
    <arm_group_label>DOXIL/CAELYX in combination with VELCADE (bortezomib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin hydrochloride (DOXIL/CAELYX)</intervention_name>
    <description>mg/m^2 by i.v. infusion will be given on Day 4 of every 21-day cycle after the administration of bortezomib (VELCADE) for up to 8 cycles.</description>
    <arm_group_label>DOXIL/CAELYX in combination with VELCADE (bortezomib)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with multiple myeloma who have received at least 1 prior therapy and who have
             either responded and later had progressive disease or have progressed during their
             first therapy (primary refractory) are eligible for the study

          -  Patients who may have received prior doxorubicin but not more than a cumulative dose
             of 240 milligram per meter square (mg/m^2) doxorubicin, DOXIL, or the equivalent
             amount of another anthracycline (i.e., 1 mg doxorubicin = 1 mg DOXIL/CAELYX = 1.8 mg
             epirubicin = 0.3 mg mitoxantrone = 0.25 mg idarubicin)

          -  Must have normal cardiac function, as evidenced by a left LVEF within institutional
             normal limits.

        Exclusion Criteria:

          -  History of treatment with VELCADE or progressive disease while receiving an
             anthracycline-containing regimen

          -  No change in disease status during initial therapy

          -  No treatment for malignancy within past 5 yrs (other than multiple myeloma) or
             progressive disease while receiving anthracycline-containing regimen

          -  Non-secretory disease

          -  Myocardial infarct within past 6 months

          -  No major surgery in past 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC C. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Alabaster</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Surprise</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stuart</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Altanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>N Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ciudad De Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mendoza</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Darlinghurst</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perth</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wels N/A</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mont-Godinne</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>N/a N/a</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olomouc</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 2 N/A</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Angers Cedex 1 N/A</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Creteil N/A</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille Cedex N/A</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nantes N/A</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pierre Benite</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rehovot</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amersfoort</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam Zuidoost</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Delft</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto N/A</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arkhangelsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Izhevsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow N/A</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nizhny Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Obninsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bloemfontein N/A</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parktown</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria Gauteng</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bath</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
    <country>New Zealand</country>
  </removed_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2005</study_first_submitted>
  <study_first_submitted_qc>February 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2005</study_first_posted>
  <results_first_submitted>May 8, 2015</results_first_submitted>
  <results_first_submitted_qc>May 8, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 25, 2015</results_first_posted>
  <last_update_submitted>September 28, 2015</last_update_submitted>
  <last_update_submitted_qc>September 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Doxil</keyword>
  <keyword>Caelyx</keyword>
  <keyword>Doxorubicin</keyword>
  <keyword>Velcade</keyword>
  <keyword>Bortezomib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Velcade (Bortezomib) Monotherapy</title>
          <description>Velcade (bortezomib) 1.3 milligram/meter per square (mg/m^2) by rapid (bolus) intravenous (IV) administration given on Day 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles.</description>
        </group>
        <group group_id="P2">
          <title>Doxil/Caelyx Plus Velcade (Bortezomib)</title>
          <description>Velcade (bortezomib) 1.3 mg/m^2 by rapid (bolus) IV administration given on Day 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles. Doxorubicin hydrochloride (DOXIL/CAELYX) 30 mg/m^2 by IV infusion will be given on Day 4 of every 21-day cycle after the administration of VELCADE (bortezomib) up to 8 cycles.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="322"/>
                <participants group_id="P2" count="324"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="322"/>
                <participants group_id="P2" count="324"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study closed by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="257"/>
                <participants group_id="P2" count="253"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Velcade (Bortezomib) Monotherapy</title>
          <description>Velcade (bortezomib) 1.3 milligram/meter per square (mg/m^2) by rapid (bolus) intravenous (IV) administration given on Day 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles.</description>
        </group>
        <group group_id="B2">
          <title>Doxil/Caelyx Plus Velcade (Bortezomib)</title>
          <description>Velcade (bortezomib) 1.3 mg/m^2 by rapid (bolus) IV administration given on Day 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles. Doxorubicin hydrochloride (DOXIL/CAELYX) 30 mg/m^2 by IV infusion will be given on Day 4 of every 21-day cycle after the administration of VELCADE (bortezomib) up to 8 cycles.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="322"/>
            <count group_id="B2" value="324"/>
            <count group_id="B3" value="646"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.5" spread="9.56"/>
                    <measurement group_id="B2" value="61.4" spread="9.61"/>
                    <measurement group_id="B3" value="61.4" spread="9.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                    <measurement group_id="B2" value="135"/>
                    <measurement group_id="B3" value="283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="174"/>
                    <measurement group_id="B2" value="189"/>
                    <measurement group_id="B3" value="363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>ARGENTINA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUSTRALIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUSTRIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BELGIUM-LUXEMBURG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CANADA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CZECH REPUBLIC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRANCE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GREAT BRITAIN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ISRAEL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ITALY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NETHERLANDS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POLAND</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PORTUGAL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RUSSIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SINGAPORE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SOUTH AFRICA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPAIN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UNITED STATES OF AMERICA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Progression (TTP)</title>
        <description>Median time to progression of disease is assessed according to International Myeloma Working Group (IMWG) criteria or death from any cause. IMWG criteria: increase of &gt;=25% from lowest level in Serum M-component or (the absolute increase must be &gt;=0.5 gram per deciliter [g/dL]); Urine M component or (the absolute increase must be &gt;=200 milligram per 24 hour. Only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels. The absolute increase &gt;10 mg/dL. Bone marrow plasma cell percentage &gt;=10%. Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing. Development of hypercalcemia. Participants who died or dropped out due to any reason without progression will be censored with the day of death or drop-out, respectively and who are alive at the end of the study without any progression was censored with the last available date.</description>
        <time_frame>Up to 1 year and 4 months (From date of first participant randomization [20 December 2004] up to interim analysis cut-off date [28 April 2006])</time_frame>
        <population>Intent-to-treat (ITT) included all the randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Velcade (Bortezomib) Monotherapy</title>
            <description>Velcade (bortezomib) 1.3 milligram/meter per square (mg/m^2) by rapid (bolus) intravenous (IV) administration given on Day 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles.</description>
          </group>
          <group group_id="O2">
            <title>Doxil/Caelyx Plus Velcade (Bortezomib)</title>
            <description>Velcade (bortezomib) 1.3 mg/m^2 by rapid (bolus) IV administration given on Day 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles. Doxorubicin hydrochloride (DOXIL/CAELYX) 30 mg/m^2 by IV infusion will be given on Day 4 of every 21-day cycle after the administration of VELCADE (bortezomib) up to 8 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression (TTP)</title>
          <description>Median time to progression of disease is assessed according to International Myeloma Working Group (IMWG) criteria or death from any cause. IMWG criteria: increase of &gt;=25% from lowest level in Serum M-component or (the absolute increase must be &gt;=0.5 gram per deciliter [g/dL]); Urine M component or (the absolute increase must be &gt;=200 milligram per 24 hour. Only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels. The absolute increase &gt;10 mg/dL. Bone marrow plasma cell percentage &gt;=10%. Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing. Development of hypercalcemia. Participants who died or dropped out due to any reason without progression will be censored with the day of death or drop-out, respectively and who are alive at the end of the study without any progression was censored with the last available date.</description>
          <population>Intent-to-treat (ITT) included all the randomized participants.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="322"/>
                <count group_id="O2" value="324"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" lower_limit="5.6" upper_limit="7.1"/>
                    <measurement group_id="O2" value="9.3" lower_limit="8.2" upper_limit="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>The OS is defined as the time from the date of first dose of study drug to date of death from any cause. If the participant is alive or the vital status is unknown, the participant will be censored at the date the participant will be last known to be alive.</description>
        <time_frame>Up to 9 years and 5 months (From date of first participant randomization [20 December 2004] to cut-off date for final survival analysis (16 May 2014)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Velcade (Bortezomib) Monotherapy</title>
            <description>Velcade (bortezomib) 1.3 milligram/meter per square (mg/m^2) by rapid (bolus) intravenous (IV) administration given on Day 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles.</description>
          </group>
          <group group_id="O2">
            <title>Doxil/Caelyx Plus Velcade (Bortezomib)</title>
            <description>Velcade (bortezomib) 1.3 mg/m^2 by rapid (bolus) IV administration given on Day 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles. Doxorubicin hydrochloride (DOXIL/CAELYX) 30 mg/m^2 by IV infusion will be given on Day 4 of every 21-day cycle after the administration of VELCADE (bortezomib) up to 8 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>The OS is defined as the time from the date of first dose of study drug to date of death from any cause. If the participant is alive or the vital status is unknown, the participant will be censored at the date the participant will be last known to be alive.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="322"/>
                <count group_id="O2" value="324"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.8" lower_limit="25.2" upper_limit="36.5"/>
                    <measurement group_id="O2" value="33.0" lower_limit="28.9" upper_limit="37.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events (SAEs)</title>
        <description>A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
        <time_frame>Up to 1 year and 11 months (From date of first participant randomization [20 December 2004] to cut-off date for safety update (28 November 2006)</time_frame>
        <population>Safety population included all the participants who received at least one dose of study drug. Here N (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Velcade (Bortezomib) Monotherapy</title>
            <description>Velcade (bortezomib) 1.3 milligram/meter per square (mg/m^2) by rapid (bolus) intravenous (IV) administration given on Day 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles.</description>
          </group>
          <group group_id="O2">
            <title>Doxil/Caelyx Plus Velcade (Bortezomib)</title>
            <description>Velcade (bortezomib) 1.3 mg/m^2 by rapid (bolus) IV administration given on Day 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles. Doxorubicin hydrochloride (DOXIL/CAELYX) 30 mg/m^2 by IV infusion will be given on Day 4 of every 21-day cycle after the administration of VELCADE (bortezomib) up to 8 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events (SAEs)</title>
          <description>A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
          <population>Safety population included all the participants who received at least one dose of study drug. Here N (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="318"/>
                <count group_id="O2" value="318"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Safety population included all the participants who received at least one dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Velcade (Bortezomib) Monotherapy</title>
          <description>Velcade (bortezomib) 1.3 milligram/meter per square (mg/m^2) by rapid (bolus) intravenous (IV) administration given on Day 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles.</description>
        </group>
        <group group_id="E2">
          <title>Doxil/Caelyx Plus Velcade (Bortezomib)</title>
          <description>Velcade (bortezomib) 1.3 mg/m^2 by rapid (bolus) IV administration given on Day 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles. Doxorubicin hydrochloride (DOXIL/CAELYX) 30 mg/m^2 by IV infusion will be given on Day 4 of every 21-day cycle after the administration of VELCADE (bortezomib) up to 8 cycles.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 9.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="120" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Cardio-Respiratory Arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Nodal Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Right Ventricular Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal Insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Hypercorticoidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Inappropriate Antidiuretic Hormone Secretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Corneal Erosion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Retinal Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Gastroduodenal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Ileus Paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Large Intestine Perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Rectal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Rectal Prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Small Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Upper Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Catheter Related Complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>General Physical Health Deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Influenza Like Illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Multi-Organ Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Sudden Cardiac Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Sudden Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Bacterial Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Bronchitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Bronchitis Chronic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Catheter Related Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Diarrhoea Infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Ear Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Genitourinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Herpes Zoster Disseminated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Klebsiella Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Lobar Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Meningitis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Neutropenic Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Opportunistic Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Pneumococcal Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Pneumococcal Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Pneumocystis JiroveCI Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Pneumonia Aspergillus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Pneumonia Legionella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Pneumonia Pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Pseudomonas Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Septic Embolus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Skin Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Staphylococcal Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Drug Toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Skeletal Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Spinal Compression Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Thoracic Vertebral Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Blood Glucose Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Ejection Fraction Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Troponin I Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Bone Lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Joint Instability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Pathological Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Colon Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Tumour Lysis Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Autonomic Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Balance Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Cauda Equina Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Cerebral Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Cerebral Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Cerebral Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Coordination Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Lumbar Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Neuropathy Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Paraplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Polyneuropathy in Malignant Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Quadriparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Spinal Cord Compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Completed Suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus Bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Nephritis Interstitial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Renal Colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Renal Failure Chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Renal Impairment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Urinary Bladder Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign Prostatic Hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Pulmonary Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Dyspnoea Exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Interstitial Lung Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Pulmonary Fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Pulmonary Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Pulmonary Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Epidermal Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Jessner's Lymphocytic Infiltration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Palmar-Plantar Erythrodysaesthesia Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Swelling Face</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 9.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="299" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="313" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="113" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="104" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="122" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="142" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="125" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="152" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="115" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Influenza Like Illness</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Herpes Simplex</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Weight Decreased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Neuropathy Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Peripheral Sensory Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Palmar-Plantar Erythrodysaesthesia Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="318"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="318"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="318"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study stopped in terms of primary endpoint based on its results at planned interim analysis (28 Apr 2006). However, Long-term follow-up for survival continued until 16 May 2014.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Project Physician</name_or_title>
      <organization>Janssen R&amp;D UK</organization>
      <email>ClinicalTrialDisclosure@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

